WO1992008347A1 - Agent cryoprotecteur - Google Patents

Agent cryoprotecteur Download PDF

Info

Publication number
WO1992008347A1
WO1992008347A1 PCT/US1990/006527 US9006527W WO9208347A1 WO 1992008347 A1 WO1992008347 A1 WO 1992008347A1 US 9006527 W US9006527 W US 9006527W WO 9208347 A1 WO9208347 A1 WO 9208347A1
Authority
WO
WIPO (PCT)
Prior art keywords
cellular matter
cell
cellular
matter
cryoprotectant
Prior art date
Application number
PCT/US1990/006527
Other languages
English (en)
Inventor
Kelvin G. M. Brockbank
Original Assignee
Cryolife, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/182,367 external-priority patent/US5071741A/en
Application filed by Cryolife, Inc. filed Critical Cryolife, Inc.
Priority to PCT/US1990/006527 priority Critical patent/WO1992008347A1/fr
Publication of WO1992008347A1 publication Critical patent/WO1992008347A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts

Definitions

  • the present invention relates to the field of cryopreservation. More specifically, disclosed is a novel class of nonpermeating cryoprotectants which can be used in combination with a permeating cryoprotectant to provide protection of living cells during the cryopreservation process, yielding improved viability.
  • Cellular matter or “cell” refers to a living structure, composed of a mass of protoplasm, enclosed in a membrane and containing a nucleus. It may or may not be part of a larger structure.
  • tissue means a collection of similar cells and the intercellular substances surrounding them. There are four basic tissues in the human body: (1) epithelium; (2) connective tissues, including blood, bone and cartilage; (3) muscle tissue; and (4) nerve tissue.
  • cryoprotectant refers to chemical compounds which are added to biological samples in order to minimize the deleterious effects of cryopreservation procedures.
  • “Osmotic effects” refers to the alteration in the osmotic strength of the suspending media caused by conversion of water to ice or ice to water. This conversion results in substantial flow of water across membranes of unfrozen cells, causing volume changes during freezing and thawing.
  • “Viability” refers to the ability of frozen and thawed cells to perform their normal functions. Viability is usually expressed as the ability of the cells to reproduce, metabolize, exclude vital dyes or carry out some other metabolic function. The viability of the frozen and thawed samples should always be compared to the ability of unfrozen cells obtained at the same time to carry out the same function.
  • transplantation and implantation procedures involving such tissues as heart valve, cornea, pancreas, skin, blood vessel, tendon/ligament, bone, bone marrow, nerve and others.
  • the major advances in transplantation of tissues are occurring because of efficient sterile procurement techniques, recognition of a group of immunologically privileged tissues, development of techniques for the avoidance of the transplant recipient's immune surveillance system, and improvements in tissue preservation methods. Storage of this tissue has become more important to enable physicians to procure and match tissues with recipients.
  • the net result of combining optimal cooling rates and cryoprotective agents is that less of the freezable intracellular water will be converted to ice and osmotic cellular dehydration is limited.
  • Permeating cryoprotective agents such as DMSO and glycerol, act by penetrating the cell membrane and reducing the intracellular water concentration, thereby reducing the amount of ice formed at any temperature.
  • nonpermeating protective agents include such compounds as polyvinylpyrrolidone, hydroxyethyl starch, monosaccharides, and sugar alcohols.
  • permeating and nonpermeating cryoprotectants act directly on the cell membranes. The mechanism of the nonpermeating cryoprotectants is not clear, but may involve changes in colloidal osmotic pressure and modifications of the behavior of membrane associated water by ionic interaction. For some cells, combination of these two classes of cryoprotective agents may give optimal viability.
  • the present invention relates to a novel class of compounds useful in the cryoprotection of living cells and tissues. More particularly, the present invention comprises the use of algae-derived polysaccharides as a class of nonpermeating cryoprotectants. These naturally occurring polysaccharides, known as agaroses and alginates, can be isolated from certain algae. These substances are bio edically important, because, while remaining biologically inert, they can form a gel matrix for diffusion and electrokinetic movement of water and biopolymers. It is believed that the gel matrix organizes the extracellular water and therefore enforces a less destructive order on the ice formed during cooling and warming. These polysaccharides are readily available in dry powder form and are easily prepared as a solution.
  • Non-permeating cryoprotectants in general apparently act on the cell membrane. This protection may be due to colloidal osmotic pressure forces exerted by large molecules and alterations in the activity of the unfrozen intercellular water caused by hydrogen bonding of these molecules to water.
  • algae-derived polysaccharides are used in conjunction with a permeating cryoprotectant such as DMSO or glycerol.
  • Permeating cryoprotectants are effective in minimizing damage to slowly frozen biological systems. By replacing water as an intracellular fluid with DMSO deleterious ice crystal formation is reduced.
  • the combination of an algae-derived polysaccharide and a permeating cryoprotectant act to provide a novel cryoprotectant with a synergistic protective effect.
  • the present invention relates broadly to the field of cryopreservation, and more particularly to the use of macromolecular polysaccharides as a nonpermeating cryoprotectant when used in conjunction with a permeating cryoprotectant.
  • the macromolecular polysaccharide is composed of nonhydrolyzed saccharide molecules linked together to form long chains.
  • the macromolecule can be composed of from about three to 3,000 saccharide molecules, more preferably from about 300 to 1200.
  • algae-derived polysaccharides are used. These include agarose and alginate.
  • Agarose is derived from agar, which is extracted from various types of red algae seaweed belonging to the group Rhodophyceae. Structurally, agarose is a purified linear galactan hydrocolloid. Different agarose preparations vary significantly with respect to their physical and chemical properties, depending upon the genus of Rhodophyta used.
  • Alginates are derived from algin, obtained from the brown seaweeds of the group Phaeophyceae. Alginate is extracted from seaweed with a strong solution of a sodium salt. Alternatively, alginic acid may be reduced with bases to give the salts and reacted with propylene oxide to make propylene glycol alginate. Both Rhodophyceae and Phaeophyceae seaweeds grow off the coasts of most continents. The giant kelp Macrocystis pyrifera, which grows in abundance along the coasts of North and South America, New Zealand, Australia and Africa, is one of the principal sources of the world's supply of algin. Algin is composed of three kinds of polymer segments.
  • One segment consists essentially of D-mannuronic acid units connected by B-l-4 linkages; a second segment consists essentially of L-glucuronic acid units; and the third segment consists of alternating D-mannuronic acid and L-glucuronic acid residues.
  • a gel is defined as a system which resembles a solid in its ability to retain its shape, and resist stress owing to a cross-linked network of polymer chains which form at gelpoints.
  • the gel consists of about 97.5 to 99% water plus solutes and 0.3 to 2.5% polymer.
  • these polysaccharides When gelled, these polysaccharides are useful as nonpermeating cryoprotectants because they provide protection for the cell. It is believed that the gel matrix orders extracellular ice formation in a manner which results in less mechanical ice-induced tissue damage. The gel matrix allows for diffusion and electrokinetic movement of water and biopolymers, while remaining essentially biologically inert.
  • the permeating cryoprotectant of the present invention is any suitable material, preferably glycerol or DMSO or combinations thereof.
  • concentration of glycerol can range from about 0.5 to 3 molar, preferably about 1 molar.
  • DMSO is highly permeable to the cell membranes and usually can be mixed directly with the samples at the appropriate concentrations or added stepwise. Stepwise addition may reduce the possibility of osmotic shock to the cell due to sharp increases in the extracellular osmolarity. It is preferable, but not mandatory, to perform the cryoprotectant addition steps at a low temperature (4*C or lower), because the agents are often toxic to the cell if added at room temperature.
  • the length of time required for osmotic equilibrium at 4 ⁇ C is substantially longer than at 37*C, but this may result in less stress to the cell and therefore higher viability.
  • a solution comprising a mixture of algae-derived polysaccharide and DMSO is prepared.
  • the solution in which the tissue is frozen is of great importance for maintaining a balanced cell environment. Time and temperature also contribute to whether a particular medium will be successful.
  • a protein suspension such as blood serum or artificial serum, must also be present for maximum cell viability.
  • a number of freezing media can be successfully used in practicing the present invention.
  • Media such as balanced tissue culture medium or simple phosphate buffered saline can be used for most tissue types.
  • Dulbecco's Minimum Essential Medium (“DMEM”) is the preferred medium plus fetal calf serum (“FCS”) of from about 1% to 30%, more preferably 10% FCS and algae derived polysaccharide having a concentration of from about 0.05% to 5%, preferably 0.1% to 3%, more preferably 0.2% to 2%.
  • DMSO is also added either in at least one step of 1M or preferably in three steps of .25M, .SM and 1M titrations at 4* C.
  • Concentrations of DMSO can range from about 0.5 to 3 molar. The increase in molarity of DMSO should preferably be gradual so as not to traumatize the tissue. DMSO can be added at higher temperatures but timing becomes far more critical and toxicity may result in some tissues.
  • co-cryoprotectants examples include, but are not limited to, hyaluronic acid, dermatan sulfate, heparin sulfate, chondroitin sulphate, and heparin, glycerol, polyvinyl pyrrolidone, hydroxyethyl starch, polyethylene glycol, dimethylformamide, ethyl glycol and the like.
  • a variety of cellular and tissue matter can be cryoprotected using the composition of the present invention.
  • living matter includes, but is not limited to, islets of Langerhans, endothelial cells, saphenous veins, arteries, heart valves, liver cells, heart valves, corneas, pancreas, skin, bone, bone marrow, nerve, connective tissue such as ligaments, tendons and cartilage, endocrine and exocrine glands, and the like.
  • the present invention also comprises a method for cryopreserving viable cellular matter using the cryoprotectant disclosed herein.
  • the cryopreservation process includes the general steps of (1) preparing the cellular matter with a cryoprotectant; (2) freezing the cells; (3) storing the frozen cells; and (4) thawing the cells.
  • transplantation the cells or tissue are recovered from a donor body or other source and cryopreserved. Following thawing of the material and removal of the cryoprotectants, the cells or tissue are implanted in a recipient body. In order to obtain maximum cell viability, the cryopreservation process must be carefully controlled and monitored.
  • Each type of cell or tissue has a unique freezing and thawing profile based on the particular intracellular makeup, intercellular organization, and the types and concentrations of cryoprotectants employed.
  • An example of a particular freezing profile for blood vessels is disclosed in appending application Serial No. 088,092 (which is expressly incorporated by reference herein) .
  • the rate of change from room temperature to 1-2 ⁇ C below the freezing point of the solution may have a major effect on ultimate viability if the cells are sensitive to thermal shock.
  • the sample is normally induced to freeze either by the introduction of an ice crystal, by touching the surface of the media with a cold probe, by mechanical vibration, or by rapidly lowering the temperature until ice nucleation occurs. Since freezing is an exothermic process, heat must be conducted away from the freezing solution. This may be done either by keeping the samples immersed in a liquid with a low freezing point or by providing a substantial heat sink. As ice forms in the extracellular media, more and more free water becomes bound in the ice phase.
  • Cell membranes being hydrophobic, act as a barrier for the nucleation of intracellular ice and therefore unfrozen cells are exposed to an increasingly hypertonic solution.
  • the extracellular salt concentration increases as a consequence of water sequestration into ice.
  • the unfrozen cells shrink due to the transport of water out of the cell in response to the osmotic imbalance between the intracellular and extracellular fluid phases.
  • the sample is then cooled at a finite rate which must be optimized for each cell type.
  • the optimal rate of cooling is determined by the permeability of the cell membrane to water, the surface-to-volume ratio of the cell, along with the type and concentration of cryoprotective additives. For most nucleated mammalian cells frozen in glycerol or DMSO, the optimal cooling, rate usually is between about 0.3 to 10 ⁇ C per minute. Continuous cooling between about 4 C and -80 ⁇ C is the most commonly used. Once the sample reaches approximately -80 C, it can be transferred directly into liquid nitrogen (-196 C) or into the vapor phase of liquid nitrogen for storage.
  • the duration of viable cell storage at liquid nitrogen temperature is dependent predominantly on the rate of generation of free radicals caused by the cosmic ray background.
  • the half-life for mammalian embryos stored in liquid nitrogen has been estimated to be approximately 30,000 years. It is important not to allow frozen cells to warm above their storage temperature for even brief periods of time. Intermittent warming promotes rapid migratory recrystallization, which can damage cellular structure and decrease overall viability.
  • the optimal rate of thawing of the sample is dependent on the freezing conditions used. In general, for single cells frozen in suspension, and for tissues such as heart valves, a rapid rate of warming is desirable. Such rapid warming limits the growth of ice crystals in the frozen samples and is often an absolute requirement for high survival. With many tissues this warming can be accomplished by agitating the sample in a 37-42 ⁇ C water bath. The rationale for rapid warming is that it limits the growth of ice crystals which were formed during cooling. Some tissues may be sensitive to rapid warming. This is due to transient osmotic shock, because the cells are exposed to an extracellular hypertonic solution as the ice melts and are forced to rehydrate in order to maintain their osmotic equilibrium. For other, more sensitive, samples, metabolic processes can be reactivated or brought up to normal levels by successive dilutions using serum or other high molecular weight polymers in the thawing medium.
  • cryoprotective agents which must be gradually diluted to return the cells to an isotonic media. This also reduces dilution induced osmotic shock.
  • a stepwise dilution protocol is typically used. The dilution of the sample is normally carried out at preferably 4 C, so as to reduce the effects of both osmotic shock and cryoprotectant toxicity.
  • glycerol When glycerol is used, care must be taken to insure complete mixing of the physiological salt solution with the cryoprotective solution. Overly rapid dilution can result in the cells being exposed to a potentially damaging osmotic stress while very slow dilution may result in toxicity to the cells from prolonged exposure to the cryoprotective agent(s) .
  • viability One of the most crucial factors in any cryobiological procedure is defining the term "viability". That definition should include one or more critical functions that accurately reflect how the cell normally carries out its biological function. The ultimate test for viability is the reproduction of the cell through two or more generations after freezing. Thus, in the case of mammalian embryos, the birth of a healthy animal (or person) is a far more definitive assay than quantitative changes in, for example, cytochrome B reductase levels. For many cell types, however, assays of cell division are not practical. For example, since polymorphonuclear leukocytes do not divides, other integrated structure/function assays must be used.
  • assays for chemotaxis, phagocytosis, reduction of nitroblue tetrazolium dye or the generation of superoxide radicals are more appropriate because they require that both the structural cellular machinery and the cellular enzymatic systems be intact.
  • relatively simple, organized tissues such as islets of Langerhans, the release of insulin in response to a differential glucose challenge is an excellent indication of functional viability.
  • the present invention can be used in a method for transplanting cryopreserved cellular matter from a donor body to a recipient body.
  • cellular matter is first removed from a donor using standard removal techniques. Then an effective amount of the algae-derived polysaccharide is added to the cell mass which is then gelled by cooling or by adding divalent cations.
  • a penetrating cryoprotectant is added to the gel-enclosed cellular matter and then frozen according to an appropriate freezing profile. The frozen cells are stored in appropriate container until they are to be transplanted.
  • the frozen cells are thawed when needed for transplantation.
  • the thawed cells are encapsulated according to known procedures in order to reduce the likelihood of rejection or creating an immune response by the recipient.
  • the encapsulated cells are implanted in the recipient by standard techniques. This transplantation method is particularly useful with islets of Langerhans.
  • Droplets, 500 to 700 microns in diameter, of alginate containing aggregates of islets of Langerhans derived from murine pancreas were encapsulated with poly-L-lysine by the process previously described by Lim (U.S. Patent No. 4,409,331 which is incorporated by reference herein) .
  • the encapsulated islet cells were then placed in a solution containing 10% fetal calf serum and 1/4 molar DMSO for 5 minutes. After 5 minutes, the suspension was changed for one containing 1/2 molar DMSO, and after a further 5 minutes, the encapsulated islets were placed in a final solution of l molar DMSO and 10% serum in culture medium.
  • DMSO is freely diffusable in encapsulated islets, and this combination of 1 molar DMSO and alginate permitted successful cryopreservation of the murine islets.
  • the islets were cryopreserved at a rate of approximately 1 degree per minute to -80 ⁇ C.
  • the islets were then placed into a liquid nitrogen storage tank at -196 C. After two weeks at this temperature, the encapsulated islets were thawed in a 37 C waterbath, and then the DMSO was removed by gradual dilution with culture medium and 10% fetal calf serum.
  • the capsules were then placed in the peritoneal cavities of C57black/J mice which had previously been made diabetic with the drug Streptozotocin (Sigma Chemical Company, St. Louis, Missouri) .
  • Streptozotocin Sigma Chemical Company, St. Louis, Missouri
  • glucose levels were definitely diabetic; i.e., >400 mg/dl of blood prior to transplantation. Thereafter, blood glucose levels were measured at irregular intervals, and on all occasions, the blood glucose levels were in the non-diabetic range, indicating that the cryopreserved islets were functioning, and therefore viable.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Nouvelle catégorie d'agents cryoprotecteurs non perméables, qui lorsqu'ils sont mélangés avec certains agents cryoprotecteurs pénétrants, fournissent un milieu utile pour protéger des cellules vivantes durant un processus de cryoconservation. Des polysaccharides dérivés d'algues, tels que l'agarose et l'alginate, sont utiles en tant qu'agents cryoprotecteurs non perméables car ils forment une matrice de gel lorsqu'ils sont refroidis, protègent contre la formation de cristaux de glace et assurent une viabilité améliorée des cellules après le dégel.
PCT/US1990/006527 1988-04-18 1990-11-08 Agent cryoprotecteur WO1992008347A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US1990/006527 WO1992008347A1 (fr) 1988-04-18 1990-11-08 Agent cryoprotecteur

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/182,367 US5071741A (en) 1988-04-18 1988-04-18 Cryoprotective agent and its use in cryopreservation of cellular matter
PCT/US1990/006527 WO1992008347A1 (fr) 1988-04-18 1990-11-08 Agent cryoprotecteur

Publications (1)

Publication Number Publication Date
WO1992008347A1 true WO1992008347A1 (fr) 1992-05-29

Family

ID=26781786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/006527 WO1992008347A1 (fr) 1988-04-18 1990-11-08 Agent cryoprotecteur

Country Status (1)

Country Link
WO (1) WO1992008347A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035472A1 (fr) * 1996-03-25 1997-10-02 Advanced Reproduction Technologies, Inc. Utilisation d'arabinogalactane dans des milieux de cryoconservation de cellules
US5879875A (en) * 1996-06-14 1999-03-09 Biostore New Zealand Compositions and methods for the preservation of living tissues
US5962213A (en) * 1996-06-14 1999-10-05 Biostore New Zealand Limited Compositions and methods for the preservation of living tissues
US6037116A (en) * 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials
US6114107A (en) * 1996-06-14 2000-09-05 Biostore New Zealand Limited Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues
WO2001050851A2 (fr) * 2000-01-14 2001-07-19 Biolife Solutions, Inc. Conservation et stockage de cellules, de tissus et d'organes dans un milieu a base de gel par normothermie, hypothermie et cryopreservation
US6361933B1 (en) 1996-06-14 2002-03-26 Biostore New Zealand Limited Solutions for the preservation of tissues
EP1269840A1 (fr) * 2000-03-24 2003-01-02 Menicon Co., Ltd. Procede de conservation d'equivalent au tissu et equivalent au tissu conserver a l'etat congele
US6743575B2 (en) 1996-06-14 2004-06-01 Biostore New Zealand Ltd. Compositions and methods for the preservation of living tissues
WO2004098287A1 (fr) * 2003-05-05 2004-11-18 Professor Sigge & Martin Ab Composition et revetement de protection
US7112576B1 (en) 1999-12-10 2006-09-26 Regents Of The University Of Minnesota Compositions and methods for cryopreservation of peripheral blood lymphocytes
WO2012035250A1 (fr) * 2010-09-16 2012-03-22 Immunobank N.V. Procede de traitement de cellules en vue de leur cryogenisation et procede de cryopreservation de cellules mettant en oeuvre un tel procede.
WO2013107797A1 (fr) * 2012-01-17 2013-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Cryoconservation de cellules, tissus et organes
WO2019156601A1 (fr) * 2018-02-08 2019-08-15 Al Otaibi Noha Abdullah S Agent cryo-additif à haute efficacité pour améliorer la bioconservation de cellules de mammifères
US10448631B2 (en) 2015-09-22 2019-10-22 East Carolina University Cryopreservation using sucralose
CN111657267A (zh) * 2020-06-17 2020-09-15 科瑞百奥泰州生物技术有限公司 一种用于软骨，肌腱，半月板保存的无冰晶冷冻保存液和冷冻方法
CN115024310A (zh) * 2022-07-19 2022-09-09 首都医科大学宣武医院 一种细胞冻干保存剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758382A (en) * 1968-07-26 1973-09-11 Us Navy Ve agent process of freezing blood using a hydroxyalkyl starch as cryoprotecti
US4004975A (en) * 1975-12-30 1977-01-25 The United States Of America As Represented By The Secretary Of The Navy Method of isolating and cryopreserving human white cells from whole blood
US4473552A (en) * 1981-03-16 1984-09-25 Jost Leonora I Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells
US4840891A (en) * 1986-09-03 1989-06-20 Genetic Engineering, Inc. Encapsulation of sperm for artificial insemination
US4874690A (en) * 1988-08-26 1989-10-17 Cryopharm Corporation Lyophilization of red blood cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758382A (en) * 1968-07-26 1973-09-11 Us Navy Ve agent process of freezing blood using a hydroxyalkyl starch as cryoprotecti
US4004975A (en) * 1975-12-30 1977-01-25 The United States Of America As Represented By The Secretary Of The Navy Method of isolating and cryopreserving human white cells from whole blood
US4473552A (en) * 1981-03-16 1984-09-25 Jost Leonora I Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells
US4840891A (en) * 1986-09-03 1989-06-20 Genetic Engineering, Inc. Encapsulation of sperm for artificial insemination
US4874690A (en) * 1988-08-26 1989-10-17 Cryopharm Corporation Lyophilization of red blood cells

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593138B1 (en) 1996-03-25 2003-07-15 Bio-Origyn Llc Cryopreserving somatic cells with an arabinogalactan containing cryopreservation medium
US5897987A (en) * 1996-03-25 1999-04-27 Advanced Reproduction Technologies, Inc. Use of arabinogalactan in cell cryopreservation media
WO1997035472A1 (fr) * 1996-03-25 1997-10-02 Advanced Reproduction Technologies, Inc. Utilisation d'arabinogalactane dans des milieux de cryoconservation de cellules
US5879875A (en) * 1996-06-14 1999-03-09 Biostore New Zealand Compositions and methods for the preservation of living tissues
US5962213A (en) * 1996-06-14 1999-10-05 Biostore New Zealand Limited Compositions and methods for the preservation of living tissues
US6037116A (en) * 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials
US6114107A (en) * 1996-06-14 2000-09-05 Biostore New Zealand Limited Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues
US6361933B1 (en) 1996-06-14 2002-03-26 Biostore New Zealand Limited Solutions for the preservation of tissues
US6743575B2 (en) 1996-06-14 2004-06-01 Biostore New Zealand Ltd. Compositions and methods for the preservation of living tissues
US7112576B1 (en) 1999-12-10 2006-09-26 Regents Of The University Of Minnesota Compositions and methods for cryopreservation of peripheral blood lymphocytes
WO2001050851A2 (fr) * 2000-01-14 2001-07-19 Biolife Solutions, Inc. Conservation et stockage de cellules, de tissus et d'organes dans un milieu a base de gel par normothermie, hypothermie et cryopreservation
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
WO2001050851A3 (fr) * 2000-01-14 2001-12-27 Biolife Solutions Inc Conservation et stockage de cellules, de tissus et d'organes dans un milieu a base de gel par normothermie, hypothermie et cryopreservation
EP1269840A1 (fr) * 2000-03-24 2003-01-02 Menicon Co., Ltd. Procede de conservation d'equivalent au tissu et equivalent au tissu conserver a l'etat congele
EP1269840A4 (fr) * 2000-03-24 2009-05-06 Menicon Co Ltd Procede de conservation d'equivalent au tissu et equivalent au tissu conserver a l'etat congele
WO2004098287A1 (fr) * 2003-05-05 2004-11-18 Professor Sigge & Martin Ab Composition et revetement de protection
FR2964981A1 (fr) * 2010-09-16 2012-03-23 Inst Europ Expertise In Physiology Procede de traitement de cellules en vue de leur cryogenisation et procede de cryopreservation de cellules mettant en oeuvre un tel procede.
WO2012035250A1 (fr) * 2010-09-16 2012-03-22 Immunobank N.V. Procede de traitement de cellules en vue de leur cryogenisation et procede de cryopreservation de cellules mettant en oeuvre un tel procede.
WO2013107797A1 (fr) * 2012-01-17 2013-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Cryoconservation de cellules, tissus et organes
US9521839B2 (en) 2012-01-17 2016-12-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Cryopreservation of cells, tissues and organs
US10448631B2 (en) 2015-09-22 2019-10-22 East Carolina University Cryopreservation using sucralose
US11185069B2 (en) 2015-09-22 2021-11-30 East Carolina University Cryopreservation using sucralose
US11284615B2 (en) 2015-09-22 2022-03-29 East Carolina University Cryopreservation using sucralose
WO2019156601A1 (fr) * 2018-02-08 2019-08-15 Al Otaibi Noha Abdullah S Agent cryo-additif à haute efficacité pour améliorer la bioconservation de cellules de mammifères
CN111657267A (zh) * 2020-06-17 2020-09-15 科瑞百奥泰州生物技术有限公司 一种用于软骨，肌腱，半月板保存的无冰晶冷冻保存液和冷冻方法
CN115024310A (zh) * 2022-07-19 2022-09-09 首都医科大学宣武医院 一种细胞冻干保存剂及其制备方法

Similar Documents

Publication Publication Date Title
US5071741A (en) Cryoprotective agent and its use in cryopreservation of cellular matter
WO1992008347A1 (fr) Agent cryoprotecteur
Karow Jr Cryoprotectants–a new class of drugs
KR100361357B1 (ko) 배양된 조직등가물의 동결보존법
JP4031044B2 (ja) 細胞凍結保存培地中のアラビノガラクタンの使用
Franks Biological freezing and cryofixation
US6632666B2 (en) Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
Bank et al. Basic principles of cryobiology
SE503182C2 (sv) Komposition lämpad för konservering och lagring av ett organ avsett för implantation i en patient, förfarande för konservering därmed och användning därav
Echlin et al. Polymeric cryoproteetants in the preservation of biological ultrastructure: II. Physiological effects
JP7398434B2 (ja) 試料と細胞外氷との直接接触を防ぐのに有効な凍結保存装置
CN113854280B (zh) 一种低温保存液及其制备方法和应用
Hunt et al. Optimising cryopreservation protocols for haematopoietic progenitor cells: a methodological approach for umbilical cord blood
Brockbank et al. Storage of tissues by vitrification
Taylor et al. Vitrification fulfills its promise as an approach to reducing freeze-induced injury in a multicellular tissue
Bujia et al. Determination of viability of cryopreserved cartilage grafts
Cook et al. Cold-storage of synthetic human epidermis in HypoThermosol
CN114190367B (zh) 冻存液及其制备方法与在免疫细胞的应用
Halberstadt et al. Corneal cryopreservation with dextran
CN112602703B (zh) 一种细胞、组织或器官冷保存液的制备方法与应用
CN115053891A (zh) 一种细胞冻存液及实施方法
Denysova et al. Cryopreservation of canine erythrocytes using dimethyl sulfoxide, polyethylene glycol and sucrose
AU The use of glycerol for preservation of living cells at low temperatures.
Matsumura et al. 7 Cell and Materials Interface in Cryobiology and Cryoprotection
Kneteman et al. Prolonged cryopreservation of purified human pancreatic islets

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB GR HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA